Pharmaceutical vendor convicted of illegal sales of $ 300,000 cholesterol drug
Illinois man who sold expensive drug for Cambridge-based Aegerion Pharmaceuticals Inc. was convicted Thursday by Boston U.S. District Court on nine counts of wire fraud and six counts of aggravated identity theft .
Prosecutors said Mark Moffett, 47, stole doctors’ identities to falsify test results, creating false clinical histories and false diagnoses.
He sold a cholesterol drug called Juxtapid, which costs $ 300,000 for a year of treatment. Moffett received up to $ 11,000 in bonuses for every prescription written by his medical clients.
According to prosecutors, Juxtapid is a cholesterol-lowering drug approved by the Food and Drug Administration only for people with a rare genetic condition. As part of his program, Moffett convinced some doctors to prescribe the drug to people who did not fit the FDA profile.
“He ignored the serious consequences this could have had on the health of patients, being more concerned with lining his pockets,” US Attorney Andrew Lelling said in a statement after the trial. “Mr. Moffett’s conviction is part of our continued efforts to hold pharmaceutical companies accountable for violating laws that protect patient safety and the integrity of the healthcare system.
The potential sentence for wire fraud can be up to 20 years per count, with three years of supervised release. Aggravated identity theft carries a mandatory minimum sentence of two years on each count, to be served consecutively to any other jail term imposed.
Judge William Young has set the sentence for April 9.